Trastuzumab-related cardiotoxicity in patients with nonlimiting cardiac comorbidity.

Rossella MartinelloPaolo BeccoPatrizia ViciMario AiroldiLucia Del MastroOrnella GarroneCarla BaroneLaura PizzutiAlessia D'AlonzoElisa BelliniAndrea MilaniAlessandro BonzanoFilippo Montemurro

Published in: The breast journal (2019)

Caution is needed in patients with significant ongoing cardiovascular risk factors, but when adjuvant trastuzumab is deemed beneficial on breast cancer outcomes, nonlimiting cardiac comorbidity should not preclude treatment.

Keyphrases

cardiovascular risk factors
epidermal growth factor receptor
left ventricular
metabolic syndrome
cardiovascular disease
early stage
metastatic breast cancer
heart failure
type diabetes
skeletal muscle
young adults
glycemic control
chemotherapy induced